Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvio Garattini

Showing results (41-50 of 165) with videos related to

Pageof 17
Sort By:
European Journal of Internal Medicine|July 19, 2018
Funding is not enoughSilvio Garattini, Vittorio Bertele'
European Journal of Clinical Pharmacology|January 30, 2008
Do we learn the right things from clinical trials?Silvio Garattini, Vittorio Bertele'
Lancet (London, England)|January 11, 2005
Discontinuation of VioxxSilvio Garattini, Vittorio Bertelé
Lancet (London, England)|August 14, 2009
Homoeopathy: not a matter for drug-regulatory authoritiesSilvio Garattini, Vittorio Bertelé
Acta Psychiatrica Scandinavica|May 9, 2006
Mild depression in general practice: is the automatism of antidepressant prescribing an evidence-based approach?Corrado Barbui, Silvio Garattini
The New England Journal of Medicine|September 16, 2010
Dutasteride and prostate cancerSilvio Garattini, Vittorio Bertele'
European Journal of Internal Medicine|November 16, 2012
The European Commission should require better medicines, not just faster reimbursementsSilvio Garattini, Vittorio Bertele'
Cancer Treatment Reviews|June 28, 2014
The pharmacological point of view of resistance to therapy in tumorsGiovanna Damia, Silvio Garattini
European Journal of Clinical Pharmacology|April 9, 2024
Paving the way towards medicines for women and menRita Banzi, Silvio Garattini
BMJ (Clinical Research Ed.)|July 15, 2010
Bevacizumab and ranibizumab. A matter of public interestSilvio Garattini, Vittorio Bertele'
Pageof 17

Showing results (41-50 of 165) with videos related to

Sort By:
Pageof 17
European Journal of Internal Medicine|July 19, 2018
Funding is not enoughSilvio Garattini, Vittorio Bertele'
European Journal of Clinical Pharmacology|January 30, 2008
Do we learn the right things from clinical trials?Silvio Garattini, Vittorio Bertele'
Lancet (London, England)|January 11, 2005
Discontinuation of VioxxSilvio Garattini, Vittorio Bertelé
Lancet (London, England)|August 14, 2009
Homoeopathy: not a matter for drug-regulatory authoritiesSilvio Garattini, Vittorio Bertelé
Acta Psychiatrica Scandinavica|May 9, 2006
Mild depression in general practice: is the automatism of antidepressant prescribing an evidence-based approach?Corrado Barbui, Silvio Garattini
The New England Journal of Medicine|September 16, 2010
Dutasteride and prostate cancerSilvio Garattini, Vittorio Bertele'
European Journal of Internal Medicine|November 16, 2012
The European Commission should require better medicines, not just faster reimbursementsSilvio Garattini, Vittorio Bertele'
Cancer Treatment Reviews|June 28, 2014
The pharmacological point of view of resistance to therapy in tumorsGiovanna Damia, Silvio Garattini
European Journal of Clinical Pharmacology|April 9, 2024
Paving the way towards medicines for women and menRita Banzi, Silvio Garattini
BMJ (Clinical Research Ed.)|July 15, 2010
Bevacizumab and ranibizumab. A matter of public interestSilvio Garattini, Vittorio Bertele'
Pageof 17